These stocks aren't going out of style.
The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.
The company is relying on several building blocks to return to growth.
Governments and physicians around the globe struggle to deliver high quality healthcare at a reasonable price. But fresh medical technology innovators are coming, and there's one in particular worth looking at.
Shares of the Botox competitor could correct/consolidate after a recent surge.
With the stock split a fresh look at the split adjusted stock is now in order.
Shares rise as much as 6.6% on the session.
TheStreet's Editors reveal what they'll be watching for during the President's speech.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.